These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

948 related items for PubMed ID: 19164213

  • 1. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F, Lopez-Crapez E, Di Fiore F, Thezenas S, Ychou M, Blanchard F, Lamy A, Penault-Llorca F, Frébourg T, Michel P, Sabourin JC, Boissière-Michot F.
    J Clin Oncol; 2009 Mar 01; 27(7):1122-9. PubMed ID: 19164213
    [Abstract] [Full Text] [Related]

  • 2. Genetic polymorphisms of FcγRIIa and FcγRIIIa are not predictive of clinical outcomes after cetuximab plus irinotecan chemotherapy in patients with metastatic colorectal cancer.
    Park SJ, Hong YS, Lee JL, Ryu MH, Chang HM, Kim KP, Ahn YC, Na YS, Jin DH, Yu CS, Kim JC, Kang YK, Kim TW.
    Oncology; 2012 Mar 01; 82(2):83-9. PubMed ID: 22327884
    [Abstract] [Full Text] [Related]

  • 3. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
    Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M.
    Cancer Sci; 2010 Sep 01; 101(9):2048-53. PubMed ID: 20550522
    [Abstract] [Full Text] [Related]

  • 4. Fc gamma receptor polymorphisms as predictive markers of Cetuximab efficacy in epidermal growth factor receptor downstream-mutated metastatic colorectal cancer.
    Rodríguez J, Zarate R, Bandres E, Boni V, Hernández A, Sola JJ, Honorato B, Bitarte N, García-Foncillas J.
    Eur J Cancer; 2012 Aug 01; 48(12):1774-80. PubMed ID: 22305465
    [Abstract] [Full Text] [Related]

  • 5. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
    Loupakis F, Pollina L, Stasi I, Ruzzo A, Scartozzi M, Santini D, Masi G, Graziano F, Cremolini C, Rulli E, Canestrari E, Funel N, Schiavon G, Petrini I, Magnani M, Tonini G, Campani D, Floriani I, Cascinu S, Falcone A.
    J Clin Oncol; 2009 Jun 01; 27(16):2622-9. PubMed ID: 19398573
    [Abstract] [Full Text] [Related]

  • 6. The role of KRAS mutations in predicting the efficacy of cetuximab-plus-irinotecan therapy in irinotecan-refractory Korean metastatic colorectal cancer patients.
    Sohn BS, Kim TW, Lee JL, Ryu MH, Chang HM, Kang YK, Park HS, Na YS, Jang SJ, Kim JC, Lee JS.
    Oncology; 2009 Jun 01; 77(3-4):224-30. PubMed ID: 19738388
    [Abstract] [Full Text] [Related]

  • 7. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC, Uen YH, Wu DC, Lu CY, Yu FJ, Wu IC, Lin SR, Wang JY.
    Ann Surg; 2010 Feb 01; 251(2):254-60. PubMed ID: 20010090
    [Abstract] [Full Text] [Related]

  • 8. Prospective Evaluation of Cetuximab-Mediated Antibody-Dependent Cell Cytotoxicity in Metastatic Colorectal Cancer Patients Predicts Treatment Efficacy.
    Trotta AM, Ottaiano A, Romano C, Nasti G, Nappi A, De Divitiis C, Napolitano M, Zanotta S, Casaretti R, D'Alterio C, Avallone A, Califano D, Iaffaioli RV, Scala S.
    Cancer Immunol Res; 2016 Apr 01; 4(4):366-74. PubMed ID: 26817995
    [Abstract] [Full Text] [Related]

  • 9. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H, Shimodaira H, Gamoh M, Ando H, Isobe H, Suto T, Takahashi S, Kakudo Y, Amagai K, Mori T, Watanabe M, Yamaguchi T, Kato S, Ishioka C.
    Oncology; 2014 Apr 01; 87(1):7-20. PubMed ID: 24968756
    [Abstract] [Full Text] [Related]

  • 10. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab.
    Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E.
    J Clin Oncol; 2012 Oct 10; 30(29):3570-7. PubMed ID: 22734028
    [Abstract] [Full Text] [Related]

  • 11. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ.
    Eur J Cancer; 2010 Jul 10; 46(10):1829-34. PubMed ID: 20418097
    [Abstract] [Full Text] [Related]

  • 12. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.
    Crit Rev Oncol Hematol; 2011 Jun 10; 78(3):243-51. PubMed ID: 20619672
    [Abstract] [Full Text] [Related]

  • 13. Fc gamma receptor IIIa polymorphisms in advanced colorectal cancer patients correlated with response to anti-EGFR antibodies and clinical outcome.
    Calemma R, Ottaiano A, Trotta AM, Nasti G, Romano C, Napolitano M, Galati D, Borrelli P, Zanotta S, Cassata A, Castello G, Iaffaioli VR, Scala S.
    J Transl Med; 2012 Nov 21; 10():232. PubMed ID: 23171437
    [Abstract] [Full Text] [Related]

  • 14. Genetic modulation of the Let-7 microRNA binding to KRAS 3'-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab-irinotecan.
    Graziano F, Canestrari E, Loupakis F, Ruzzo A, Galluccio N, Santini D, Rocchi M, Vincenzi B, Salvatore L, Cremolini C, Spoto C, Catalano V, D'Emidio S, Giordani P, Tonini G, Falcone A, Magnani M.
    Pharmacogenomics J; 2010 Oct 21; 10(5):458-64. PubMed ID: 20177422
    [Abstract] [Full Text] [Related]

  • 15. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F.
    J Clin Oncol; 2011 May 20; 29(15):2011-9. PubMed ID: 21502544
    [Abstract] [Full Text] [Related]

  • 16. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
    Asai H, Shinozaki E, Nozaki A, Watanabe T, Suenaga M, Matuzaka S, Chin K, Mizunuma N, Yasukawa M, Hatake K.
    Gan To Kagaku Ryoho; 2011 Aug 20; 38(8):1285-91. PubMed ID: 21829065
    [Abstract] [Full Text] [Related]

  • 17. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V.
    J Clin Oncol; 2011 Mar 10; 29(8):1050-8. PubMed ID: 21300933
    [Abstract] [Full Text] [Related]

  • 18. The importance of KRAS mutations and EGF61A>G polymorphism to the effect of cetuximab and irinotecan in metastatic colorectal cancer.
    Garm Spindler KL, Pallisgaard N, Rasmussen AA, Lindebjerg J, Andersen RF, Crüger D, Jakobsen A.
    Ann Oncol; 2009 May 10; 20(5):879-84. PubMed ID: 19179548
    [Abstract] [Full Text] [Related]

  • 19. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.
    Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E, Floriani I, Bencardino K, Galluccio N, Catalano V, Tonini G, Magnani M, Fontanini G, Basolo F, Falcone A, Graziano F.
    Br J Cancer; 2009 Aug 18; 101(4):715-21. PubMed ID: 19603018
    [Abstract] [Full Text] [Related]

  • 20. Clinical usefulness of KRAS, BRAF, and PIK3CA mutations as predictive markers of cetuximab efficacy in irinotecan- and oxaliplatin-refractory Japanese patients with metastatic colorectal cancer.
    Soeda H, Shimodaira H, Watanabe M, Suzuki T, Gamoh M, Mori T, Komine K, Iwama N, Kato S, Ishioka C.
    Int J Clin Oncol; 2013 Aug 18; 18(4):670-7. PubMed ID: 22638623
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 48.